Fair Value Distribution — percentile bands
7.3% of simulations place fair value above current price
WHAT IS PRICED IN
Revenue-Based Reverse DCF
9.6%/yr
±5.4% · revenue growth to justify current price
FCF-Based Reverse DCF
8.2%/yr
±3.1% · FCF growth to justify current price
THE GAP
Market pricing margin expansion or capex normalization
KEY VALUE DRIVERS
Spearman correlation — what moves this valuation most
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide.
No Eagle analysis yet. Request a full review including conviction score, bull/bear cases, and thesis.
No analysis yet
No analysis yet
Abbott delivered solid FY2025 results led by CGM dominance (.6B, +17%) and MedDevices segment growth (+12%), with expanding operating margins (16.3%→18.2%). The transformative pending acquisition of E...